Four new relevant AOPs were identified: AOP 495 “Androgen receptor activation leading to prostate cancer,” AOP 496 “Androgen receptor agonism leading to reproduction dysfunction in zebrafish,” AOP 503 “Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation,” and AOP 504 “SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level.” All four AOPs include some KEs and AOs that were not previously described in the AOPN and will be considered when the AOPN is further developed. This evidence concerns the gene AR and prostate carcinoma.